Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab: A Global Population-Based Study across 65 Countries.
Lakhani Moiz, Popovic Marko M, Al-Ani Abdullah, Kundapur Deeksha, Gholamian Tara, Chaudry Emaan et al.
This study compared ocular adverse events of aflibercept 8mg, faricimab, and aflibercept 2mg. Aflibercept 8mg showed strong signals for intraocular inflammation and infection, while other agents had different safety profiles, highlighting drug-specific risks.